MedDay Announces Full Enrollment for MD1003 Phase III

Biotin is an emerging therapy for the treatment of secondary progressive MS.
Post Reply
User avatar
ton
Family Member
Posts: 75
Joined: Thu May 27, 2010 2:00 pm

MedDay Announces Full Enrollment for MD1003 Phase III

Post by ton » Fri Nov 09, 2018 11:14 am


Post Reply
  • Similar Topics
    Replies
    Views
    Last post
  • Ibudilast phase II successful
    by NHE » Fri Aug 31, 2018 3:39 pm » in Drug Pipeline
    1 Replies
    1261 Views
    Last post by Zyklon
    Sat Sep 01, 2018 9:24 am
  • Ublituximab Phase II Success
    by NHE » Thu Mar 07, 2019 5:10 pm » in Drug Pipeline
    2 Replies
    71 Views
    Last post by zen2010
    Fri Mar 08, 2019 1:17 am